A top 5 global pharmaceutical company with a presence in 155 countries faced challenges in leveraging cloud technology for regulated processes. The absence of a formal Software Development Lifecycle (SDLC) for their Azure DevOps environment and limited guidance on compliance processes restricted their ability to innovate in clinical trials.
The Challenge
The company wanted to use AI chatbots to speed and sharpen the delivery of GxP content to clinical sites, but its Microsoft Azure DevOps environment lacked the validated foundation regulated workflows require. Without a formal SDLC, there was no defensible path to qualify the tooling for GxP use, and no clear guidance on how to keep AI-driven processes compliant.
- No dedicated SDLC or standard operating procedures (SOPs) for GxP use cases in Microsoft Azure DevOps.
- Limited understanding of how to validate AI and DevOps tools for GxP environments, a core concern for computer software assurance.
- A need for automated AI chatbots to improve the speed and accuracy of delivering GxP content to clinical sites.
The Approach
The pharmaceutical company partnered with USDM to implement a validated AI framework for Microsoft Azure, creating a continuously compliant infrastructure for regulated processes. The work paired hands-on AI delivery with the governance scaffolding that 21 CFR Part 11-regulated environments demand:
- Developing an AI pilot program using Azure NLP tools for GxP-compliant chatbot implementation.
- Building governance structures and workflows tailored for GxP use cases.
- Integrating native eSignature functionality in Azure to streamline approval processes while preserving data integrity.
- Creating a Master Assurance Plan (MAP) to clearly delineate GxP, non-GxP, and Software as a Medical Device (SaMD) processes, enabling formal and informal testing to meet regulatory requirements.
The Results
By treating validation as an enabler rather than a roadblock, the company turned its Azure environment into a launchpad for AI in clinical trials. The measurable outcomes spanned efficiency, speed, cost, and user experience.
Enhanced Operational Efficiency
- Deployment of GxP-compliant AI chatbots reduced the time to provide critical regulatory information to clinical sites by 30%.
- The automation of approvals using native Azure eSignatures eliminated the need for custom software development, cutting implementation costs by 20%.
Accelerated Innovation in Clinical Trials
- Qualification of Azure DevOps tools for GxP applications enabled the company to develop and deploy new solutions 40% faster than traditional methods.
- The governance framework ensured continuous compliance, reducing time spent on audits and regulatory validations by 25%.
Strategic Cost Savings
- The Master Assurance Plan allowed the company to optimize testing protocols, saving an estimated $1.5 million annually on compliance-related expenses.
- Leveraging existing Azure infrastructure reduced overhead costs for non-GxP applications by an additional 15%.
Improved User Experience
- The AI chatbots provided clinical sites with instant, accurate GxP information, increasing user satisfaction scores by 35%.
- The intuitive workflows and automated approval processes enhanced team productivity and decision-making.
By leveraging USDM's expertise, the pharmaceutical company not only met but exceeded regulatory compliance requirements, unlocking AI's potential to transform its clinical trial operations. These measurable business outcomes underscore the strategic importance of integrating validated AI solutions in regulated environments. Ready to bring the same rigor to your AI initiatives? Connect with USDM to get started.